Germany Recordati Rare Diseases aims to be a trusted partner in helping patients with rare diseases reach diagnosis and appropriate care sooner Rapid access to innovation alone does not solve the rare disease challenge in Germany. Despite being one of Europe’s most advanced pharmaceutical markets, patients still face long diagnostic journeys…
MEA Khaled Elrefae of Recordati Rare Diseases discusses how the company is expanding its rare disease footprint across Saudi Arabia, the GCC, and the wider MENA region. He highlights the region’s high unmet medical needs, the strategic steps taken to accelerate product launches, and the role of partnerships, diagnostics, and genomics…
France In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state subsidies in rival markets. “France’s industrial fabric risks being systematically hollowed out if we don’t act fast to mitigate…
France France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as a benchmark internationally, and which few other countries have proven able to match. “Back in the mid-2000s, under the…
France Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses, playing host to virtually all top-tier, big-brand biopharma. Yet alongside its well-forged reputation for sophisticated healthcare infrastructure, manufacturing excellence, and…
France France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and home to some of the continent’s most influential patient organisations. More than three million French citizens live with one of…
France With only a handful of patients affected by each condition, rare diseases present a unique set of scientific, medical, and economic challenges. At the heart of this complex landscape is Recordati Rare Diseases, whose European headquarters and manufacturing footprint are anchored in France. General Manager Jean-Claude Roche shares his perspective…
Saudi Arabia Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom now commands nearly a third of the entire MENA pharma market. But this story goes far beyond impressive numbers. Through…
Saudi Arabia With MENA’s healthcare landscape evolving rapidly, Recordati is expanding its presence, particularly in Saudi Arabia and the GCC, where regulatory advancements and a growing focus on rare diseases are creating new opportunities. Khaled Elrefae, General Manager MENA, is leading efforts to accelerate patient access, strengthen local expertise, and shape the…
Italy A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC Pharma; Menarini’s oncology partnership with Insilico Medicine, and Angelini’s brain health deal with Cureverse. Italian drug maker Recordati boosts…
Turkey İsmail Yormaz, Recordati’s VP and regional director for south-east, highlights how the Milan-based company has become a shining example of a successful localization strategy, upcoming launches and investments, as well as some of the challenges that the firm is facing in Turkey, including the country’s challenging pricing system. The…
Turkey Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the country’s Health Transformation Program introduced in 2003, has been commended by international organizations across the world. But today, as citizens…
See our Cookie Privacy Policy Here
